Psychological stress assessment of patients suffering from prostate cancer

Seklehner, Stephan; Hladschik-Kermer, Birgit; Lusuardi, Lukas; Schabauer, Christoph; Riedl, Claus R.; Engelhardt, Paul F.

doi:10.3109/00365599.2012.700946

Cited by 19 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The varied evidence for the association of waiting times with short- and longer-term outcomes implies that the cut off times of these targets are somewhat arbitrary, with 31 and 62 days having little biological relevance: indeed, some studies point out the difficulty of showing a difference in outcomes that depends on short time differences [ 26 , 30 ]. However, there is general agreement that intervals between referral, diagnosis and treatment should be minimised, as every effort should be made to reduce the anxiety experienced by patients while waiting, however long that is [ 8 – 10 , 24 , 29 ]. Murchie et al point out that the publicity surrounding waiting times could itself engender anxiety when patients have to wait past the ‘cut-off’ [ 27 ], and this anxiety can have wider impacts: a recent study reported the highest mortality rates among the most distressed cancer patients [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Intervals between referral for suspicion of cancer, confirmation of diagnosis and beginning of treatment are indicators of quality in cancer care: the time patients have to wait between these events have been scrutinised for many years [ 1 – 7 ]. Delays in waiting times have the potential both to induce worry and anxiety, which worsens patient experience [ 8 – 10 ], and to influence patient outcomes [ 11 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Can we assess Cancer Waiting Time targets with cancer survival? A population-based study of individually linked data from the National Cancer Waiting Times monitoring dataset in England, 2009-2013

et al. 2018

View full text Add to dashboard Cite

BackgroundCancer Waiting Time targets have been integrated into successive cancer strategies as indicators of cancer care quality in England. These targets are reported in national statistics for all cancers combined, but there is mixed evidence of their benefits and it is unclear if meeting Cancer Waiting Time targets, as currently defined and published, is associated with improved survival for individual patients, and thus if survival is a good metric for judging the utility of the targets.Methods and findingsWe used individually-linked data from the National Cancer Waiting Times Monitoring Dataset (CWT), the cancer registry and other routinely collected datasets. The study population consisted of all adult patients diagnosed in England (2009–2013) with colorectal (164,890), lung (171,208) or ovarian (24,545) cancer, of whom 82%, 76%, and 77%, respectively, had a CWT matching record.The main outcome was one-year net survival for all matched patients by target attainment (‘met/not met’). The time to each type of treatment for the 31-day and 62-day targets was estimated using multivariable analyses, adjusting for age, sex, tumour stage and deprivation.The two-week wait (TWW) from GP referral to specialist consultation and 31-day target from decision to treat to start of treatment were met for more than 95% of patients, but the 62-day target from GP referral to start of treatment was missed more often. There was little evidence of an association between meeting the TWW target and one-year net survival, but for the 31-day and 62-day targets, survival was worse for those for whom the targets were met (e.g. colorectal cancer: survival 89.1% (95%CI 88.9–89.4) for patients with 31-day target met, 96.9% (95%CI 96.1–91.7) for patients for whom it was not met). Time-to-treatment analyses showed that treatments recorded as palliative were given earlier in time, than treatments with potentially curative intent.There are possible limitations in the accuracy of the categorisation of treatment variables which do not allow for fully distinguishing, for example, between curative and palliative intent; and it is difficult in these data to assess the appropriateness of treatment by stage. These limitations in the nature of the data do not affect the survival estimates found, but do mean that it is not possible to separate those patients for whom the times between referral, decision to treat and start of treatment could actually have an impact on the clinical outcomes. This means that the use of these survival measures to evaluate the targets would be misleading.ConclusionsBased on these individually-linked data, and for the cancers we looked at, we did not find that Cancer Waiting Time targets being met translates into improved one-year survival. Patients may benefit psychologically from limited waits which encourage timely treatment, but one-year survival is not a useful measure for evaluating Trust performance with regards to Cancer Waiting Time targets, which are not currently stratified by stage or treatment type. As such, the...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Can we assess Cancer Waiting Time targets with cancer survival? A population-based study of individually linked data from the National Cancer Waiting Times monitoring dataset in England, 2009-2013

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although studies of prostate cancer often focus on functional outcomes of therapy, the extent to which adverse effects bother men also needs careful evaluation (Luckett et al , 2009; Pachman et al , 2012; Seklehner et al , 2012). Understanding the importance of comprehensive patient outcomes is essential in delivering whole-patient cancer care (Jacobsen et al , 2012; Stanton, 2012).…”

mentioning

confidence: 99%

The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries

Cockle-Hearne

Charnay-Sonnek

Denis³

et al. 2013

Br J Cancer

View full text Add to dashboard Cite

Background:Prostate cancer is for many men a chronic disease with a long life expectancy after treatment. The impact of prostate cancer therapy on men has been well defined, however, explanation of the consequences of cancer treatment has not been modelled against the wider variables of long-term health-care provision. The aim of this study was to explore the parameters of unmet supportive care needs in men with prostate cancer in relation to the experience of nursing care.Methods:A survey was conducted among a volunteer sample of 1001 men with prostate cancer living in seven European countries.Results:At the time of the survey, 81% of the men had some unmet supportive care needs including psychological, sexual and health system and information needs. Logistic regression indicated that lack of post-treatment nursing care significantly predicted unmet need. Critically, men's contact with nurses and/or receipt of advice and support from nurses, for several different aspects of nursing care significantly had an impact on men's outcomes.Conclusion:Unmet need is related not only to disease and treatment factors but is also associated with the supportive care men received. Imperative to improving men's treatment outcomes is to also consider the access to nursing and the components of supportive care provided, especially after therapy.

show abstract

“…Previous studies regarding the psychological impact of prostate biopsy have reported variable results ranging from no apparent impact to most patients experiencing anxiety. [25,26] Various strategies have been suggested to reduce the psychological distress of the procedure. Wade et al [26] noted that accurate prebiopsy counseling and reassurance of the normality of some side effects (eg, hematuria, hematospermia) after prostate biopsy reduced the psychological distress (anxiety) caused by side effects.…”

Section: Discussionmentioning

confidence: 99%

Hemostatic effect and psychological impact of an oxidized regenerated cellulose patch after transrectal ultrasound-guided prostate biopsy

et al. 2019

View full text Add to dashboard Cite

To investigate the usefulness of the oxidized regenerated cellulose patch (ORCP) for postbiopsy hemostasis, anxiety, and depression in patients undergoing transrectal ultrasound-guided prostate biopsy. This was a prospective-retrospective study of 300 patients who underwent systematic 12-core prostate biopsy from August 2016 through March 2018. The ORCP was inserted into the rectum immediately after prostate biopsy in the prospective group (n = 150), while the retrospective group (n = 150) underwent prostate biopsy alone. The frequency rate and duration of hematuria, rectal bleeding, and hematospermia were compared between the 2 groups. Anxiety and depression were assessed with the hospital anxiety and depression scale before and after prostate biopsy in the prospective group. The frequency rates of hematuria and hematospermia showed no significant differences between the prospective versus retrospective groups (64.7% vs 66.7%, P = .881; 18 vs 20%, P = .718; respectively). Frequency of rectal bleeding was significantly lower in the prospective group than in the retrospective group (26.7% vs 42.7%, P = .018). However, there were no significant differences in median duration of rectal bleeding, hematuria, or hematospermia between the 2 groups (2, 5, and 2 days vs 2, 7, and 1 day, P > .05, respectively, for the prospective vs retrospective group). Multivariate analysis found that ORCP insertion was a significant protective factor against postbiopsy rectal bleeding ( P = .038, odds ratio 0.52). Only anxiety level in the prospective group before versus after prostate biopsy was significantly reduced (5 vs 4, P = .011). ORCP insertion after prostate biopsy is an effective and simple method for decreasing rectal bleeding. ORCP insertion may also alleviate anxiety in patients undergoing prostate biopsy.

show abstract

Psychological stress assessment of patients suffering from prostate cancer

Cited by 19 publications

References 30 publications

Can we assess Cancer Waiting Time targets with cancer survival? A population-based study of individually linked data from the National Cancer Waiting Times monitoring dataset in England, 2009-2013

Can we assess Cancer Waiting Time targets with cancer survival? A population-based study of individually linked data from the National Cancer Waiting Times monitoring dataset in England, 2009-2013

The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries

Hemostatic effect and psychological impact of an oxidized regenerated cellulose patch after transrectal ultrasound-guided prostate biopsy

Contact Info

Product

Resources

About